Kidney Damage Biomarkers - Ep 173

About this episode

Dr. Sandra Kane-Gill discusses novel kidney biomarkers for early detection and management of drug-induced acute kidney injury.

The mortality and economic burden of drug-induced acute kidney injury are substantial, emphasizing the need for prevention and optimal treatment. Dr. Sandra Kane-Gill provides perspective on novel kidney biomarkers and how they offer a missing piece of the assessment for early detection and management of drug-induced acute kidney injury. Read the full manuscript at: https://accpjournals.onlinelibrary.wiley.com/doi/full/10.1002/phar.70071

People in this episode

Guest: Dr Sandra Kane-Gill

Topics covered

• kidney injury
• biomarkers
• drug-induced acute kidney injury

Keywords

• mortality
• economic burden
• prevention
• treatment

More episodes of ACCP JOURNALS

• Getting Published in JACCP: Tips for Success - Ep 184 · June 9, 2026 · 28 min
• Predicting Fall Risks in Older Adults with Depression: A Machine Learning Approach - Ep 183 · May 19, 2026 · 30 min
• Reimagining Renal Assessment: Pros and Cons - Ep 182 · May 12, 2026 · 38 min
• Navigating Cardiotoxicity in Modern Cancer Therapy - Ep 181 · April 22, 2026 · 33 min
• High-Value Interventions Primary Care Practices Might Be Overlooking: Clinical Pharmacy Services – Ep 180 · April 7, 2026 · 36 min
• Enhancing Pharmacotherapy Through Artificial Intelligence: From Prediction Models to Practice – Ep 179 · March 25, 2026 · 24 min